Journal Articles

Reclassification of Cardiovascular Risk Using Integrated Clinical and Molecular Biosignatures: Design and Rationale of the MURDOCK Horizon 1 Cardiovascular Disease Study

September 12, 2010

Shah SH, Granger CB, Hauser ER, Kraus WE, Sun JL, Pieper K, Nelson CL, DeLong ER, Califf RM, Newby LK, for the MURDOCK Horizon 1 Cardiovascular Disease Investigators. Reclassification of Cardiovascular Risk Using Integrated Clinical and Molecular Biosignatures: Design and Rationale of the MURDOCK Horizon 1 Cardiovascular Disease Study. Am Heart J 2010 Sep;160(3):371-379.e2.

Abstract

BACKGROUND:

Clinical predictive models leave gaps in our ability to stratify cardiovascular risk. High-throughput molecular profiling promises to improve risk classification.

METHODS:

Horizon 1 of the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Study was conceived to apply emerging molecular techniques to existing data sets to characterize mechanistic diversity underlying complex human diseases, response to therapy, and prognosis. No previous studies have applied multiple, complementary molecular techniques in combination with well-developed clinical risk models to refine cardiovascular risk prediction. The MURDOCK Cardiovascular Disease Study will assess molecular profiles integrated with clinical data in “clinomic” profiles for cardiovascular risk classification.

CONCLUSION:

Herein, we describe the design of and rationale for the MURDOCK Cardiovascular Disease Study.

2010 Mosby, Inc. All rights reserved.

Comments are closed.

Connect With Us